Comparison

Wilms8 Cells European Partner

Für die Verwendung dieses Produktes fordert der Hersteller das zu Ihrer Institution passende, ausgefüllte und unterschriebene Formular: Bitte laden Sie dieses entweder beim Kaufabschluss hoch oder senden es alternativ an die purchasing@hoelzel.de
Item no. CLS-300416
Manufacturer CLS Cell Lines Service
Amount 1 cryovial
Category
Type Cell line
Certificate For a certificate of analysis, please send an inquiry to info@hoelzel.de.
Applications Cell Culture
Specific against Human (Homo sapiens)
Dry ice Yes
ECLASS 10.1 42040401
ECLASS 11.0 42040401
UNSPSC 41106509
Available
Manufacturer - Applications
In vitro cell culture model. Biochemical studies
Manufacturer - Category
Kidney cancer cell lines
Description
The Wilms8 cell line was derived from a primary Wilms tumor in a pediatric patient with a germline WT1 mutation. This cell line is characterized by a homozygous nonsense mutation in the WT1 gene (c.1168 C>T, p.R390X), leading to a complete loss of WT1 function. WT1 is crucial for normal kidney development, and its inactivation is a common feature in certain aggressive subtypes of Wilms tumor, particularly those that exhibit mesenchymal differentiation. Wilms8, therefore, provides a valuable model for studying the effects of WT1 loss on tumorigenesis, especially in the context of Wilms tumors that arise with a pronounced stromal component.

In addition to the WT1 mutation, Wilms8 cells harbor a mutation in the CTNNB1 gene (p.S45A), which encodes β-Catenin, a key regulator of the Wnt signaling pathway. The mutation at serine 45 disrupts the normal phosphorylation process that leads to β-Catenin degradation, causing its stabilization and accumulation in the nucleus. This results in the constitutive activation of Wnt signaling, which drives cell proliferation and contributes to the oncogenic properties of the Wilms8 cell line. The interplay between WT1 loss and aberrant Wnt signaling in Wilms8 makes it a crucial model for understanding the molecular mechanisms underlying these pathways in Wilms tumor biology.

Wilms8 cells display a mesenchymal phenotype, characterized by the expression of vimentin and the absence of epithelial markers such as cytokeratin. This aligns with the stromal differentiation observed in the original tumor. The cells demonstrate a limited ability to undergo further mesenchymal differentiation, such as forming muscle-like cells under specific conditions. Proteomic analyses of Wilms8 have revealed the activation of multiple receptor tyrosine kinases (RTKs), including PDGFRβ and AXL, which are involved in key processes such as cell survival, migration, and proliferation. The activation of downstream signaling pathways, particularly the MAPK and PI3K/AKT pathways, further contributes to the aggressive characteristics of Wilms8 cells.

Overall, the Wilms8 cell line serves as an essential tool for investigating the molecular basis of Wilms tumor driven by WT1 loss and aberrant Wnt signaling. Its genetic and phenotypic features make it a robust platform for studying the interaction between these critical pathways and for identifying potential therapeutic targets in Wilms tumors with a stromal component.
Tissue
Kidney
Growth properties
Adherent
Cell type
Wilms cells
Disease
Wilms tumor
Age
8 months
Gender
Male
Ethnicity
Caucasian
Morphology
Spindle-shaped
Biosafety Level
1
Culture Medium
MSCGM kit (from Lonza)
Medium Supplements
4 mM L-glutamine
Subculturing
Remove the old medium from the adherent cells and wash them with PBS that lacks calcium and magnesium. For T25 flasks, use 3-5 ml of PBS, and for T75 flasks, use 5-10 ml. Then, cover the cells completely with Accutase, using 1-2 ml for T25 flasks and 2.5 ml for T75 flasks. Let the cells incubate at room temperature for 8-10 minutes to detach them. After incubation, gently mix the cells with 10 ml of medium to resuspend them, then centrifuge at 300xg for 3 minutes. Discard the supernatant, resuspend the cells in fresh medium, and transfer them into new flasks that already contain fresh medium.
Freeze Medium
Handling of Cryopreserved Cultures

Confirm that the vial remains deeply frozen upon delivery, as cells are shipped on dry ice to maintain optimal temperatures during transit.

Upon receipt, either store the cryovial immediately at temperatures below -150° C to ensure the preservation of cellular integrity, or proceed to step 3 if immediate culturing is required.

For immediate culturing, swiftly thaw the vial by immersing it in a 37° C water bath with clean water and an antimicrobial agent, agitating gently for 40-60 seconds until a small ice clump remains.

Perform all subsequent steps under sterile conditions in a flow hood, disinfecting the cryovial with 70% ethanol before opening.

Carefully open the disinfected vial and transfer the cell suspension into a 15 ml centrifuge tube containing 8 ml of room-temperature culture medium, mixing gently.

Centrifuge the mixture at 300 x g for 3 minutes to separate the cells and carefully discard the supernatant containing residual freezing medium.

Gently resuspend the cell pellet in 10 ml of fresh culture medium. For adherent cells, divide the suspension between two T25 culture flasks; for suspension cultures, transfer all the medium into one T25 flask to promote effective cell interaction and growth.

Adhere to established subculture protocols for continued growth and maintenance of the cell line, ensuring reliable experimental outcomes.

Sterility
Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods.
To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections.
Safety Precautions
When planning to store a cryovial in liquid nitrogen for future thawing, it is mandatory to adhere to stringent safety measures. Appropriate protective gloves and clothing are essential, and the use of a face mask or safety goggles is required during the transfer of frozen samples to or from the liquid nitrogen tank. This is to mitigate the risk of injury from potential cryovial explosions upon removal, which can result in the projection of sharp fragments.
Disclaimer
Our cells are provided for in vitro laboratory research purposes exclusively and are not intended for clinical or diagnostic use, nor are they to be administered to humans or used for veterinary purposes. Users must adhere to all applicable guidelines and regulations for the handling and use of these cells in a research setting.
Warranty
We stand by the promise of delivering products with high cell viability and robust culture performance. To achieve the best results, please make sure you follow the storage and culture instructions detailed in the product information sheet closely. Your adherence to these guidelines is key to success.
Amelogenin
X, Y
Mutational Profile
WT1 mutation status: homozygous c.1168C|BiggerAs|T, p.390X, LOH: , CTNNB1 mutation status: heterozygous TCT|BiggerAs|GCT, p.S45A
Passaging Solution
Accutase

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 1 cryovial
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close